It is a singular choice that Chile has made in its vaccination policy.
Faced with the controversy surrounding AstraZeneca's Covid-19 vaccine, the country has decided to administer it only to men.
This is what the government announced when the country received its first shipment on Friday.
In Europe, the vaccine from the Anglo-Swedish laboratory has seen its use restricted in many countries due to very rare cases of thrombosis, mostly occurring in young patients.
Last week Chile's Institute of Public Health (ISP), which in January granted emergency authorization for the vaccine, recommended its use in women over 55 and men over 18.
But Deputy Health Secretary Paula Daza said on Friday that the vaccine "will only be given to men" from next week.
READ ALSO>
Chile in the vaccine race, an unexpected feat
The European Medicines Agency (EMA) said on Friday that after a new study, the benefits of the AstraZeneca vaccine increased with age and continued to outweigh the risks.
One of the countries where vaccination is progressing the fastest
And despite reports that cases of blood clots were more common in women, the EMA said there was "not enough data available across the EU" to say the risks are linked to the sex.
AstraZeneca technology uses an adenovirus as a vector, such as the American Johnson & Johnson, Russian Sputnik V and Chinese CanSino vaccines.
On Friday, experts from the American health authority recommended the resumption of vaccination with Johnson & Johnson's serum in the United States, suspended since April 13 after rare cases of thrombosis.
The shipment of 158,400 doses of the AstraZeneca vaccine arriving Friday is the first received by Chile under the Covax mechanism of the World Health Organization (WHO) which aims to guarantee equitable access to anti-Covid vaccines.
Chile is one of the fastest growing countries in its vaccination process. Some 7.9 million people have been vaccinated with at least one dose out of a total population of 19 million.
